anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A balanced nutrition starting from early childhood significantly influences growth and psychomotor development. Exclusive breast milk is the recommended nutritional choice from birth to 6 months of life, as it guarantees everything necessary for growth, maturation, protection from infections, promoting the development of a balanced intestinal microbiota. Several prenatal and perinatal factors including the type of delivery, the use of antibiotics, diet and other environmental factors, can influence the microbial colonization of the newborn. Thus, it is generally accepted that the gut microbiota of the healthy, full-term, vaginally born, breastfed infant is the gold standard for a favorable microbial composition in the early years of life. Human milk provides several bioactive components, from natural probiotics such as Bifidobacterium spp. and Lactobacillus spp., to their metabolites ("natural postbiotics"), which colonize the intestine of the newborn. These metabolites regulate the development of the immune system and attenuate the inflammatory processes. However, if breast milk is not available or insufficient to meet the nutritional needs of the infant, formula milk is proposed and used as a substitute. Given the benefits, it is essential that infant formula is as close to human milk as possible, providing bioactive substances that target gut and immune system health. Current research focuses on optimizing artificial formulas, with the aim of resembling human milk in composition and functionality, with some on the market already including probiotics, prebiotics, synbiotics and postbiotics. However, it still remains to be clarified which is the best formulation and the exact consequences on the immune, metabolic and microbial system of the newborn. In particular, postbiotics are preparations composed of both microbial constituents and their metabolites, produced during fermentation. It has already been highlighted in the literature that the enrichment of formula milk with post-biotics would seem to offer advantages for feeding term infants. Furthermore, it promotes an immune, metabolic and microbial component maturation, similarly to human milk, thus making postbiotic supplements very promising and interesting in the nutrition of newborns and infants.
UNLABELLED: Adult diffuse gliomas commonly recur regardless of therapy. As recurrence typically arises from the peritumoral edema adjacent to the resected bulk tumor, the profiling of somatic mutations from infiltrative malignant cells within this critical, unresected region could provide important insights into residual disease. A key obstacle has been the inability to distinguish between next-generation sequencing (NGS) noise and the true but weak signal from tumor cells hidden among the noncancerous brain tissue of the peritumoral edema. Here, we developed and validated True2 sequencing to reduce NGS-associated errors to <1 false positive/100 kb panel positions while detecting 97.6% of somatic mutations with an allele frequency ≥0.1%. True2 was then used to study the tumor and peritumoral edema of 22 adult diffuse gliomas including glioblastoma, astrocytoma, oligodendroglioma, and NF1-related low-grade neuroglioma. The tumor and peritumoral edema displayed a similar mutation burden, indicating that surgery debulks these cancers physically but not molecularly. Moreover, variants in the peritumoral edema included unique cancer driver mutations absent in the bulk tumor. Finally, analysis of multiple samples from each patient revealed multiple subclones with unique mutations in the same gene in 17 of 22 patients, supporting the occurrence of convergent evolution in response to patient-specific selective pressures in the tumor microenvironment that may form the molecular foundation of recurrent disease. Collectively, True2 enables the detection of ultralow frequency mutations during molecular analyses of adult diffuse gliomas, which is necessary to understand cancer evolution, recurrence, and individual response to therapy.
SIGNIFICANCE: True2 is a next-generation sequencing workflow that facilitates unbiased discovery of somatic mutations across the full range of variant allele frequencies, which could help identify residual disease vulnerabilities for targeted adjuvant therapies.
The Hyalgan group received intraarticular injection of 2 ml Hyalgan for three continuously weeks and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
Pilomatricoma is a benign tumor that presents as a 3-30mm firm, solitary, deep dermal or subcutaneous tumor on the head, neck, or upper extremities. The clinical diagnosis is often made by the firm, sometimes rock hard texture of the skin. The diagnosis can be confirmed by a skin biopsy and/or excision of the lesion. We have recently noted that pilomatricomas appear as a black mass in the skin when the lesion is transilluminated by placing the light of a fiberoptic otoscope adjacent to the skin lesion. We would like to confirm our impression by a prospective study using transillumination to examine subcutaneous tumors in the skin. Pilomatricoma is also known as a benign calcifying or calcified epithelioma, pilomatrixoma, or a calcifying epithelioma of Malherbe.
BACKGROUND: Ovarian cancer (OC) is a malignant neoplasm that displays increased vascularization. Angiopoietin-like 4 (ANGPTL4) is a secreted glycoprotein that functions as a regulator of cell metabolism and angiogenesis and plays a critical role in tumorigenesis. However, the precise role of ANGPTL4 in the OC microenvironment, particularly its involvement in angiogenesis, has not been fully elucidated.
METHODS: The expression of ANGPTL4 was confirmed by bioinformatics and IHC in OC. The potential molecular mechanism of ANGPTL4 was measured by RNA-sequence. We used a series of molecular biological experiments to measure the ANGPTL4-JAK2-STAT3 and ANGPTL4-ESM1 axis in OC progression, including MTT, EdU, wound healing, transwell, xenograft model, oil red O staining, chick chorioallantoic membrane assay and zebrafish model. Moreover, the molecular mechanisms were confirmed by Western blot, Co-IP and molecular docking.
RESULTS: Our study demonstrates a significant upregulation of ANGPTL4 in OC specimens and its strong association with unfavorable prognosis. RNA-seq analysis affirms that ANGPTL4 facilitates OC development by driving JAK2-STAT3 signaling pathway activation. The interaction between ANGPTL4 and ESM1 promotes ANGPTL4 binding to lipoprotein lipase (LPL), thereby resulting in reprogrammed lipid metabolism and the promotion of OC cell proliferation, migration, and invasion. In the OC microenvironment, ESM1 may interfere with the binding of ANGPTL4 to integrin and vascular-endothelial cadherin (VE-Cad), which leads to stabilization of vascular integrity and ultimately promotes angiogenesis.
CONCLUSION: Our findings underscore that ANGPTL4 promotes OC development via JAK signaling and induces angiogenesis in the tumor microenvironment through its interaction with ESM1.
Surgical Site Infection (SSI) has an enormous impact on patients' quality of life. SSIs further stresses on allocation of different health care resources and contribute significantly in terms of high cost of care. This was a prospective study carried out in tertiary care hospitals of Karachi, Pakistan, involving abdominal surgeries and few other surgeries, in patients having 20 years of age and above, were admitted from June 2016 to May 2017. Total number of 554 patients were included. Data was collected in all relevant areas including utilization pattern of antibiotics, cost in term of infected and uninfected patients, the duration of patient stay etc. Data analysis was performed using Statistical Package for the Social Sciences (SPSS) software. P value less than 0.005 was taken as significant. Single therapy of co amoxiclav or along with metronidazole and third generation cephalosporin were the most common prescribed antimicrobial groups. Amikacin most commonly used to treat post-surgical wound infection. Economic cost was high in terms of SSI patients. Duration of stay was found longer in infected patients. It can be concluded that SSI, may prolong length of hospitalization, cause morbidity, upsurge the health care cost and even may lead to mortality.
The present invention relates to an anti-tumor slow-release preparation. It is a slow-release injection formed from slow-release microsphere and solvent. The slow-release microsphere includes anti-cancer effective component and slow-release auxiliary material. The anti-cancer effective component is the combination of glucocorticoid and anti-cancer medicine selected from anti-tumor anti-biotic and/or antimetabolite medicine. The solvent is a special solvent containing suspension adjuvant, and the glucocorticoid is selected from methyl prednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, clobetasone and beclomethasone, etc. and the slow-release auxiliary material is selected from PLA, PLGA, polyethylene glycol and PLA or PLGA copolymer and fatty acid and sebacic acid copolymer, etc. which can be bio-degrable and absorbabile. The suspension adjuvant is selected from carboxy methyl cellulose, etc. and its viscosity is 80 cp-3000 cp. Said slow-release preparation also can be made into slow-release implantation preparation.
Virtual-reality based dance training - Participants received Virtual-reality based dance training for 10 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) "Just Dance 3". The first six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song. The first 6 weeks are conducted in the laboratory. The next four weeks are conducted in the participants home via telerehabilitation. The four week sessions consisted of 3 sessions/week.
PURPOSE:To enable exact decision of the presence of an ATLV antibody by using the result obtd. by using the antigen obtd. by treating an ATLV negative cell strain and making measurement with respect to a sample as contrast and making decision by comparison. CONSTITUTION:The constituting elements for the entire part of a measuring system are a solid phase, an antigen associated with ATL, the antigen of this invention, the same antibody, antihuman IgG antibody, enzyme and substrate. The cup of a microtiter plate for enzyme immonoassay or glass beads may be used for the solid phase. The antigen associated with ATL and the antigen are respectively dissolved in a physiological buffer salt soln. of 0.15M phosphoric acid and the soln. is put into, for example, a polystyrene cup for enzyme immunoassay and is allowed to stand for one hour at <=4 deg.C, then the surface of the solid phase is coated by the antigen associated to ATL and the antigen. The serum to be inspected may be added straightly into the measuring system but may be more preferably added thereto after diluting the same to, for example, 100 times by a normal rabbit serum (NRS). The measurement may be accomplished in accordance with the ordinary procedure in an enzyme immunoassay method. Overall decision is made finally.
Ketamine is a drug used for anesthesia since the 1970s, acting as an antagonist to the N-methyl-D-aspartate receptor located in the central nervous system. It has two stereoisomers : R +ketamine and S - ketamine, the latter being about two to four times more potent. S-ketamine also has the advantages of producing less psychotropic effects, less tiredness and a lower temporary cognitive impairment than the racemic mixture at equianalgesic doses. Being first used as an anesthetic, in the last twenty years, ketamine's indications expanded to other domains, such as treatment of depression or off label use for chronic pain relief. Chronic pain is a multidimensional syndrome that touches 17-44% of the population of western countries. Fibromyalgia is a cause of chronic pain, classified by the Internal Classification of Diseases (ICD) as a primary chronic pain with specific diagnostic criteria established by the American College of Rheumatology (ACR). No treatment to its complete cure is available at this time, all treatments having as purpose pain relief and an improvement of quality of life by combining pharmacologic and nonpharmacologic treatments (as given by the European League Against Rheumatism (EULAR) guidelines). One of the mechanisms proposed in fibromyalgia is the central sensitisation phenomenon, by which the central nervous system becomes "hypersensitive" to nociceptive or non-nociceptive stimuli. The receptor involved in this phenomenon is the N-methyl-D-aspartate receptor to which ketamine binds. Ketamine has therefore been proposed as a co-treatment in chronic pain with central sensitization phenomena, such as fibromyalgia.
Computer based methods, systems, and computer readable media for providing genomic services are provided. A request is received from a user. The request is applied to one or more from a group of a personalized data repository for the user and supporting knowledge bases, wherein the personalized data repository includes genetic test results, health/clinical information, and insurance coverage, and wherein the knowledge bases include information pertaining to genetic tests and clinical guidelines. Data from the applied request is integrated with results from service modules performing one or more from a group of content search, variation interpretation, and report generation to produce results for the request. The personalized data repository and supporting knowledge bases are updated based on the results of the request. Surveillance services are triggered based on one or more events.
The crucial role of high mobility group AT-hook 1 (HMGA1) proteins in nuclear processes such as gene transcription, DNA replication, and chromatin remodeling is undeniable. Elevated levels of HMGA1 have been associated with unfavorable clinical outcomes and adverse differentiation status across various cancer types. HMGA1 regulates a diverse array of biological pathways, including tumor necrosis factor-alpha/nuclear factor-kappa B (TNF-α/NF-κB), epidermal growth factor receptor (EGFR), Hippo, Rat sarcoma/extracellular signal-regulated kinase (Ras/ERK), protein kinase B (Akt), wingless-related integration site/beta-catenin (Wnt/beta-catenin), and phosphoinositide 3-kinase/protein kinase B (PI3-K/Akt). While researchers have extensively investigated tumors in the reproductive, digestive, urinary, and hematopoietic systems, mounting evidence suggests that HMGA1 plays a critical role as a tumorigenic factor in tumors across all functional systems. Given its broad interaction network, HMGA1 is an attractive target for viral manipulation. Some viruses, including herpes simplex virus type 1, human herpesvirus 8, human papillomavirus, JC virus, hepatitis B virus, human immunodeficiency virus type 1, severe acute respiratory syndrome Coronavirus 2, and influenza viruses, utilize HMGA1 influence for infection. This interaction, particularly in oncogenesis, is crucial. Apart from the direct oncogenic effect of some of the mentioned viruses, the hit-and-run theory postulates that viruses can instigate cancer even before being completely eradicated from the host cell, implying a potentially greater impact of viruses on cancer development than previously assumed. This review explores the interplay between HMGA1, viruses, and host cellular machinery, aiming to contribute to a deeper understanding of viral-induced oncogenesis, paving the way for innovative strategies in cancer research and treatment.
BACKGROUND: Catecholamines and β-adrenergic receptors (β-ARs) play an important role in the regulation of cardiac tolerance to the impact of ischemia and reperfusion. This systematic review analyzed the molecular mechanisms of the cardioprotective activity of β-AR ligands.
METHODS: We performed an electronic search of topical articles using PubMed databases from 1966 to 2023. We cited original in vitro and in vivo studies and review articles that documented the cardioprotective properties of β-AR agonists and antagonists.
RESULTS: The infarct-reducing effect of β-AR antagonists did not depend on a decrease in the heart rate. The target for β-blockers is not only cardiomyocytes but also neutrophils. β1-blockers (metoprolol, propranolol, timolol) and the selective β2-AR agonist arformoterol have an infarct-reducing effect in coronary artery occlusion (CAO) in animals. Antagonists of β1- and β2-АR (metoprolol, propranolol, nadolol, carvedilol, bisoprolol, esmolol) are able to prevent reperfusion cardiac injury. All β-AR ligands that reduced infarct size are the selective or nonselective β1-blockers. It was hypothesized that β1-AR blocking promotes an increase in cardiac tolerance to I/R. The activation of β1-AR, β2-AR, and β3-AR can increase cardiac tolerance to I/R. The cardioprotective effect of β-AR agonists is mediated via the activation of kinases and reactive oxygen species production.
CONCLUSIONS: It is unclear why β-blockers with the similar receptor selectivity have the infarct-sparing effect while other β-blockers with the same selectivity do not affect infarct size. What is the molecular mechanism of the infarct-reducing effect of β-blockers in reperfusion? Why did in early studies β-blockers decrease the mortality rate in patients with acute myocardial infarction (AMI) and without reperfusion and in more recent studies β-blockers had no effect on the mortality rate in patients with AMI and reperfusion? The creation of more effective β-AR ligands depends on the answers to these questions.
A sterile aqueous composition for parenteral administration which comprises an oil-water emulsion in which a water-immiscible solvent is emulsified with water and stabilized by means of surfactant, and which further comprises an amount of disodium edetate wherein the amount of disodium edetate is a molar concentration with respect to EDTA free acid in the range 3 . 10 exp(-5) to 9 . 10exp(-4). There is also described a sterile aqueous composition for parenteral administration which comprises an oil-water emulsion containing a therapeutic or pharmaceutical agent, in which the agent, either alone or dissolved in a water-immiscible solvent is emulsified with water and stabilized by means of surfactant, and which further comprises an amount of disodium edetate wherein the amount of disodium edetate is a molar concentration with respect to EDTA free acid in the range 3 . 10 exp(-5) to 9 . 10exp(-4).
The invention relates to a Chinese medicinal composition for relieving physical fatigue. The Chinese medicinal composition is prepared from the following raw materials in part by weight: 1.5 to 5 parts of cordyceps militaris, 1.5 to 5 parts of prepared rehmannia root, 1 to 3 parts of medlar, 1.5 to 5 parts of szechuan tangshen root and 1 to 3 parts of Chinese date. The Chinese medicinal composition is prepared according to a reasonable formula, and is exact in a curative effect of relieving the physical fatigue. The invention also relates to a preparation method for the Chinese medicinal composition. The method comprises the following steps of: decocting the cordyceps militaris individually, and drying under reduced pressure; and decocting the other four medicines, and performing spray drying to prepare a pharmaceutically-acceptable preparation. When the method is used for preparing the Chinese medicinal composition, the composition is convenient to use and controllable in quality.
The invention comprises 2-(41-isopentyloxy-phenyl imino)-3-(411isopentyloxy-phenyl-thiazolidine and physiologically tolerable acidaddition salts thereof such as those of mineral acids and perchloric and thiocyanic acids and various organic acids including formic, propionic, glycollic, lactic, pyruvic, oxalic, malonic, fumaric, tartaric, ascorbic, hydroxymaleic, phenyl acetic, amino or hydroxy benzoic, anthranilic, mandelic, phenoxy benzoic, methane sulphonic and naphthalene sulphonic acids, and methionine, tryptophane, lysine and arginine.  The thiazolidine and its salts may be prepared by reacting 1,3-bis(4-isopentoxy-phenyl)-2-thiourea with a strong inorganic or organic acid di-ester of 1,2-ethanediol yielding a salt of the desired thiazolidine from which the free base may be liberated by alkali and from which free base any desired salt may then be prepared.  The reactive ester is preferably used in excess as a solvent.  In an example, a mixture of the thiourea and excess of 1,2-dibromo ethane is refluxed, ether is then added and the precipitated gum is treated with ethanolic ammonia to recover the free thiazolidine which is heated in ethanol with oxalic acid to form the oxalate salt.  The thiazolidine and its salts may be used in antitubercular and antileprotic preparations (see Group VI).ALSO:Pharmaceutical preparations having anti-tubercular and anti-leprotic properties comprise an active ingredient 2-(41-isopentoxy-phenyl-imino)-3-(41-isopentoxy phenyl) thiazolidine or a physiologically tolerable acid addition salt thereof and a pharmaceutical carrier suitable for enteral or parenteral administration.  Salts specified include those of hydrochloric, hydrobromic, nitric, sulphuric, phosphoric, perchloric, thiocyanic, formic, acetic, propionic, glycollic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, ascorbic, hydroxymaleic, dihydroxy maleic, benzoic, phenyl acetic, 4 - amino benzoic, 4 - hydroxy benzoic, anthranilic, cinnamic, mandelic, salicylic, 4 - amino salicylic, 2 - phenoxy benzoic, 2 - acetoxy benzoic, methane sulphonic, ethane sulphonic, hydroxyethane sulphonic, benzene sulphonic, toluene sulphonic, naphthalene sulphonic and sulphanilic acids and methionine, trypto-phane, lysine and arginine.  The carrier may be a solid or liquid inorganic or organic material, numerous examples being given.  The preparations may be in the form of tablets, dragees, capsules, solutions or emulsions.  They may also comprise other therapeutic substances and stabilising, preserving, wetting or emulsifying agents.
Fine particular matter (PM2.5) and lead (Pb) exposure can induce insulin resistance, elevating the likelihood of diabetes onset. Nonetheless, the underlying mechanism remains ambiguous. Consequently, we assessed the association of PM2.5 and Pb exposure with insulin resistance and inflammation biomarkers in children. A total of 235 children aged 3-7 years in a kindergarten in e-waste recycling areas were enrolled before and during the Corona Virus Disease 2019 (COVID-19) lockdown. Daily PM2.5 data was collected and used to calculate the individual PM2.5 daily exposure dose (DED-PM2.5). Concentrations of whole blood Pb, fasting blood glucose, serum insulin, and high mobility group box 1 (HMGB1) in serum were measured. Compared with that before COVID-19, the COVID-19 lockdown group had lower DED-PM2.5 and blood Pb, higher serum HMGB1, and lower blood glucose and homeostasis model assessment of insulin resistance (HOMA-IR) index. Decreased DED-PM2.5 and blood Pb levels were linked to decreased levels of fasting blood glucose and increased serum HMGB1 in all children. Increased serum HMGB1 levels were linked to reduced levels of blood glucose and HOMA-IR. Due to the implementation of COVID-19 prevention and control measures, e-waste dismantling activities and exposure levels of PM2.5 and Pb declined, which probably reduced the association of PM2.5 and Pb on insulin sensitivity and diabetes risk, but a high level of risk of chronic low-grade inflammation remained. Our findings add new evidence for the associations among PM2.5 and Pb exposure, systemic inflammation and insulin resistance, which could be a possible explanation for diabetes related to environmental exposure.